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Background: We previously demonstrated that superparamagnetic iron oxide (SPIO)-enhanced MR imaging is
promising for the detection of metastases in sentinel nodes localized by CT-lymphography in patients with breast
cancer. The purpose of this study was to determine the predictive criteria of the size of nodal metastases with
SPIO-enhanced MR imaging in breast cancer, with histopathologic findings as reference standard.
Methods: This study included 150 patients with breast cancer. The patterns of SPIO uptake for positive sentinel
nodes were classified into three; uniform high-signal intensity, partial high-signal intensity involving ≥50% of the
node, and partial high-signal intensity involving <50% of the node. Imaging results were correlated with
histopathologic findings.
Results: Thirty-three pathologically positive sentinel nodes from 30 patients were evaluated. High-signal
intensity patterns that were uniform or involved ≥50% of the node were observed in 23 nodes that contained
macro-metastases and no node that contained micro-metastases, while high-signal intensity patterns involving
<50% of the node were observed in 2 nodes that contained macro-metastases and 8 nodes that contained
micro-metastases. When the area of high-signal intensity was compared with the pathological size of the
metastases, a pathologic >2 mm sentinel node metastases correlated with the area of high-signal intensity,
however, a pathologic ≤2 mm sentinel node metastases did not.
Conclusions: High-signal intensity patterns that are uniform or involve ≥50% of the node are features of nodes
with macro-metastases. The area of high-signal intensity correlated with the pathological size of metastases for
nodes with metastases >2 mm in this series.
Keywords: Sentinel node, Breast cancer, Magnetic resonance imaging, Computed tomography, Superparamagnetic
iron oxide, Nodal enhancement pattern, Lymph node metastasisBackground
Sentinel node biopsy is emerging as an alternative to ax-
illary lymph node dissection for patients with breast can-
cer with clinically negative nodes [1-5]. It is associated
with less morbidity, such as lymph edema and neuropa-
thies, than axillary lymph node dissection, but with high* Correspondence: motomurak@hotmail.com
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distribution, and reproduction in any mediumaccuracy in the prediction of axillary nodal status; how-
ever, it still involves a surgical procedure with associated
morbidity. Overall, 2-7% of patients are reported to have
lymphedema even after sentinel node biopsy [6-8].
Recently, intravenously administered ultrasmall super-
paramagnetic iron oxide (USPIO)-enhanced MR imaging
has been reported to be promising for the diagnosis
of lymph node metastases as a noninvasive method. Some
researchers have already evaluated nodal staging in various
tumors [9-11]. Harisinghani et al. demonstrated a sensitivitytral Ltd. This is an Open Access article distributed under the terms of the
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USPIO-enhanced MR imaging in 80 patients with prostate
cancer [9]. Rockall et al. reported that the sensitivity
for nodal staging using USPIO-enhanced MR imaging in
768 lymph nodes from 44 patients with endometrial or
cervical cancer was 100%, significantly higher than the
conventional method using size criteria, which has a sen-
sitivity of 27% [10]. Stets et al. reported an accuracy of
87%, sensitivity of 81%, and specificity of 92% using
USPIO-enhanced MR imaging for axillary lymph node
metastases in 52 lymph nodes from 9 patients with breast
cancer [11]. A recent meta-analysis demonstrated that
USPIO-enhanced MR imaging is sensitive and specific,
and superior to other modalities in the detection of nodal
metastases for various malignancies [12].
We previously assessed MR imaging using interstitial
injection of superparamagnetic iron oxide (SPIO) en-
hancement for the detection of metastases in sentinel
nodes which were localized by CT-lymphography
(CT-LG) in patients with breast cancer [13]. We demon-
strated that SPIO-enhanced MR imaging accurately
stages the axilla and may avoid even sentinel node bi-
opsy in patients with breast cancer.
In the present study, we investigated the correlation
between the area of high-signal intensity on SPIO-
enhanced MR imaging and the pathologic size of senti-
nel node metastases in breast cancer patients with
pathologically positive sentinel nodes for determining
the predictive criteria of the size of nodal metastases.
Patients and methods
Patient selection
One hundred and fifty consecutive patients with clin-
ical T1-2 breast cancers and clinically negative nodes
who underwent sentinel node biopsy at Osaka Medical
Center for Cancer and Cardiovascular Diseases be-
tween January 2008 and November 2009 were enrolled
in this study. Patients with nonpalpable breast cancer,
prior axillary surgery or who were pregnant were ex-
cluded. Patients with a contraindication to CT or MR
imaging, or a known allergy to the contrast agents were
also excluded. The institutional review board of Osaka
Medical Center for Cancer and Cardiovascular Diseases
approved the study, and written consent was obtained
from all patients.
Sentinel node localization using CT-LG
Interstitial CT-LG was performed using a multidetector
row helical CT scanner (Light Speed VCT; GE Healthcare,
Milwaukee, WI, USA). Contiguous 1.25-mm-thick CT im-
ages from the upper thorax to axillary regions were ob-
tained once before administration of the contrast agent.
CT scanning with a detector of 0.625 mm, 64 rows was
operated at 120 kV, 300 to 400 Auto-mA, 35 cm field ofview, 512 × 512 matrix, section spacing of 1 mm, and a
table speed of 1.55 mm/0.5 sec.
Transaxial CT images were reconstructed with a
1.25-mm pitch and slice thickness of 0.3 mm. Each patient
was placed in the supine position. Three small plastic
bullets were placed as landmarks on the upper chest wall
on the skin for a merged image of the CT-LG and axial MR
image. First, their arms were placed in an elevated position.
After local anesthesia with a subcutaneous injection of 2 ml
of 2% procaine hydrochloride, 6 ml iopamidol (Iopamiron
370; Bayer Schering Pharma, Osaka, Japan) was injected
intradermally into the skin overlying the breast tumor and
into the subareolar skin. A CT scan was performed after
massaging the iopamidol injection site for one minute.
Second, a CT scan was performed in the adducted arm
position. Finally, their arms were placed in an elevated
position again, and a localizing marker, which is usually
used for CT-guided lung nodule biopsy, was attached to
the skin at the axilla to identify the sentinel node location
over the skin [14]. The sentinel node location was identified
on the CT image and was indicated precisely by the cross-
ing point of the localizing marker and the CT plane lights.
The site was marked on the skin surface using an oil pen.
3D-CT images were reconstructed from the post-
contrast CT images at each time point with volume-
rendering techniques and, if necessary, a workstation
(GE Advantage Workstation, version 4.3; GE Healthcare,
Milwaukee, WI, USA) was used to further examine lymph
flow and the sentinel node (Figure 1a).
MR imaging
MR images were obtained using a 1.5 T imaging system
(Sonata/Symphony; Siemens, Erlangen, Germany) with a
12-channel matrix body coil. T1-weighted axial images
were obtained from the upper thorax to axillary lesions
(repetition time in msec (TR), 140; echo time in msec
(TE), 1.88; slice width, 4 mm; interslice gap, 0 mm; num-
ber of acquisitions, one; field of view, 28 × 28 cm; matrix,
141 × 256); T2-weighted axial images were obtained
through the axilla (TR, 4,000; TE, 85 effective time; echo
train length, 11; slice width, 4 mm; interslice gap, 0 mm;
number of acquisitions, one; field of view, 25 × 25 cm;
matrix, 250 × 384). Additional nodal imaging sequences
included T2*-weighted gradient echo images in the axial
plane (TR, 613; TE, 30; flip angle, 30; slice width, 4 mm;
interslice gap, 0 mm; number of acquisitions, one; field of
view, 25 × 25 cm; matrix, 230 × 384).
Each patient was placed in the supine position in the
adducted arm position. A 40 μl aliquot of SPIO (Resovist;
FUJIFILM RI Farma Co., Ltd., Kyobashi, Tokyo),
containing 1.115 mg iron, was diluted in 20 ml normal
saline. After local anesthesia with subcutaneous injection
of 2 ml of 2% procaine hydrochloride, 6 ml SPIO,
containing 0.3345 mg iron, was injected intradermally into
Figure 1 Sentinel node localization using CT-lymphography and SPIO-enhanced MR imaging for diagnosis. Three-dimensional
CT-lymphography reconstructed from the first post-contrast images (a). Lymphatic vessels drained into a single axillary sentinel node (arrow).
Images of CT-lymphography (b) and T2*-weighted axial MR images (c) at the same level were compared to specify the node (arrow) on
T2*-weighted axial MR imaging corresponding to the sentinel node (arrow) identified by CT-lymphography. The node (arrow) showed high-signal
intensity before administration of superparamagnetic iron oxide (SPIO). (d) After administration of SPIO, the node showed homogenous low
signal intensity and was diagnosed as benign (arrow).
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subareolar skin. The injection sites of SPIO were gently
massaged for one minute. At 18 to 24 hours after the
administration of SPIO, the T1-, T2- and T2*-weighted
sequences used for interpretation of the lymph node status
were repeated. The MR imaging interval was determined
by referring to the report of the study using USPIO [15].
T1-weighted and T2-weighted images were used for
anatomic localization; the T1-weighted image in particular
allows the shape and size of nodes clearly.
Images of the CT-LG (Figure 1b) and T2*-weighted
axial MR images (Figure 1c) in the adducted arm
position at the same level were compared to specify the
node on T2*-weighted axial MR imaging corresponding
to the sentinel node identified by CT-LG. If necessary,
a merged image of the CT-LG and T2*-weighted axial
MR images was obtained on a workstation (PEGASYS;
ADAC, Milpitas, CA, USA), with the help of small
plastic bullets.Nodes were evaluated on pre- and post-SPIO images by
1 reader (K.M.). Visual analysis was based on the diagnostic
guidelines previously reported by Anzai et al. [16]. In brief,
a node was considered non-metastatic if it showed
homogenous low-signal intensity (Figure 1d) and metastatic
if the entire node or more than 50% of the node has
high-signal intensity on post-SPIO MR imaging compared
with the signal intensity on pre-SPIO images. A node was
considered possibly metastatic if less than 50% of the node
has high-signal intensity [16]. In this study, patterns of
SPIO uptake for positive sentinel nodes were classified into
three referring to the guideline [16]; uniform high-signal
intensity, partial high-signal intensity involving more than
50% of the node, and partial high-signal intensity involving
less than 50% of the node (Figures 2, 3 and 4).
Surgery
Sentinel node biopsy was performed as described previ-
ously [17-19]. In brief, intradermal or intradermal and
Figure 2 Pattern of uniform high-signal intensity on SPIO-enhanced MR imaging. (a) The node (arrow) showed high-signal intensity before
administration of superparamagnetic iron oxide (SPIO). (b) After administration of SPIO, the node showed uniform high-signal intensity and was
diagnosed as malignant (arrow). (c) Histological findings confirmed it as malignant. This node was almost entirely replaced by metastatic tissue.
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m tin colloid the day before surgery and peritumoral
or intradermal and subareolar injection of 5 ml in-
docyanine green (ICG, Diagnogreen 0.5%; Daiichi
Pharmaceutical Co. Ltd., Nihonbashi, Tokyo, Japan)
10 minutes before surgery were performed, and then
the injection site was massaged manually for one
minute. Lymphoscintigraphy was performed 2–3 hours
after the radioisotope injection.
Breast surgery was performed before axillary surgery
in all patients to minimize the influence of radioactivity
from the injection site [17-19]. Hot nodes were identi-
fied using a gamma probe (neo2000; Neoprobe
Corporation, Dublin, OH, USA). Dyed and/or hot nodes
located just under the markers using CT images were
defined as sentinel nodes and were removed.Figure 3 Pattern of partial high-signal intensity involving more than
showed high-signal intensity before administration of superparamagnetic i
partial high-signal intensity involving more than 50% and was diagnosed a
macro-metastases within the node (arrowheads).Histopathology
Sentinel nodes were serially sectioned at 2 mm intervals.
Hematoxylin and eosin sections of these nodes were pre-
pared from each 2-mm slice. When these nodes were
tumor-negative in paraffin sections, an additional 4-μm
section was cut and stained with immunohistochemistry
(IHC) using the avidin-biotinylated peroxidase complex
technique with the mouse monoclonal antibody against
cytokeratin (NCL-CK19; Novocastra Laboratories Ltd.,
Newcastle, UK or AE1/AE3; Thermoelectron Corp.,
Waltham, MA, USA). On the basis of the 6th edition of the
Union Internacional Contra la Cancrum TNM categories,
metastatic nodes were categorized according to the degree
of metastatic burden as follows: macrometastases (>2 mm)
and micrometastases (0.2 to 2.0 mm). Nodes with isolated
tumor cells identified by IHC were considered to be50% of the node on SPIO-enhanced MR imaging. (a) The node
ron oxide (SPIO). (b) After administration of SPIO, the node showed
s malignant (arrow). (c) Histological findings showed the presence of
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high-signal intensity was compared with the patho-
logical size of the metastases.
Statistical analysis
Spearman’s rank-order correlation was used for statis-
tical analysis.
Results
The mean age of the 150 patients was 56.0 (range, 31–
79) years and the mean pathologic tumor size was 19.4
(range, 0.2–60) mm. Patient and tumor characteristics
are summarized in Table 1. The mean number of senti-
nel nodes identified by CT-LG was 1.15 (range 1–3).
The mean size of sentinel nodes was 9.6 (range, 4–25)
mm. Thirty-three pathologically positive sentinel nodes
from 30 patients were evaluated. Four false-negative
patients were excluded. Three patterns of SPIO uptake
were demonstrated for positive sentinel nodes. Six nodes
(18.2%) showed uniform high-signal intensity, 17 nodes
(51.5%) showed partial high-signal intensity involving more
than 50% of the node, and 10 nodes (30.3%) showed partial
high-signal intensity involving less than 50% of the node.
High-signal intensity patterns that were uniform or
involved more than 50% of the node were observed in 23
nodes that contained macro-metastases and no node that
contained micro-metastases, while high-signal intensity pat-
terns involving less than 50% of the node were observed in
2 nodes that contained macro-metastases and 8 nodes that
contained micro-metastases. When the area of high-signal
intensity was compared with the pathological size of the
metastases, a pathologic >2 mm sentinel node metastases
correlated with the area of high-signal intensity, however, aFigure 4 Pattern of partial high-signal intensity involving less than 50
showed high-signal intensity before administration of superparamagnetic i
partial high-signal intensity involving less than 50% and was diagnosed as
micro-metastases within the node (arrowheads).pathologic ≤2 mm sentinel node metastases did not.
(rs = 0.482, p = 0.015; rs = 0.309, p = 0.457, respectively).
Discussion
The patterns of contrast enhancement have been
demonstrated to distinguish between malignant and
benign lymph nodes using USPIO-enhanced MR images
[16]. A lymph node with an area of high-signal intensity
encompassing the entire node or a portion of it was
considered metastatic according to the diagnostic guide-
lines for USPIO-enhanced MR imaging, which are based
on qualitative analysis of the results [16]. If there is no
blackening of the node or if the node is hyperintense to
surrounding tissue, or the node has central high-signal
with darkening along the peripheral rim, or partial
darkening whereby more than 50% of the node has an
area of high-singal intensity, a node is diagnosed as
metastatic. If less than 50% of the node has high-signal
intensity, it is possibly metastatic. If the node has overall
dark signal intensity, it is diagnosed as non-metastatic. A
larger area of high-signal intensity within the node was
reported to be more likely to be metastatic on USPIO-
enhanced MR imaging. Lahaye et al. reported that an
estimated area of high-signal intensity within the node
that was more than 30% was highly predictive of a meta-
static node, with a sensitivity of 93% and a specificity of
96% in patients with primary rectal cancer [21]. They
demonstrated that the most accurate and practical pre-
dictive criterion is the estimation of the percentage of
high-signal intensity within the node on USPIO-
enhanced MR imaging. In the present study, we classi-
fied the patterns of SPIO uptake for positive sentinel
nodes into three; uniform high-signal intensity, partial% of the node on SPIO-enhanced MR imaging. (a) The node
ron oxide (SPIO). (b) After administration of SPIO, the node showed
malignant (arrow). (c) Histological findings showed the presence of
Table 1 Patient characteristics
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>5 2 1.3
Tumor location
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Upper inner 30 20.0
Lower outer 24 16.0




Invasive ductal 132 88.0
Invasive lobular 7 4.7
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node, and partial high-signal intensity involving less than
50% of the node. We demonstrated that high-signal
intensity patterns that were uniform or involved more
than 50% of the node were observed in nodes with
macro-metastases (Figures 2 and 3). High signal inten-
sity patterns involving less than 50% of the node were
often observed in nodes with micro-metastases
(Figure 4). When the area of high-signal intensity was
compared with the pathological size of the metastases, a
pathologic > 2 mm sentinel node metastases correlated
with the area of high-signal intensity, however, a patho-
logic ≤ 2 mm sentinel node metastases did not. The size
of small metastatic foci could not be assessed because
MR imaging had limited resolution in the present
setting. It may be difficult to detect micro-metastases
with a section thickness of 4 mm at this resolution on
1.5 T MR images. Interstitial administration of SPIOleads to excessive dosage or a high concentration of
SPIO, which may conceal some micro-metastatic foci,
resulting in underestimation of the size of metastatic
foci, while the fatty hilum of a node, which coexists with
metastases, may mimic a metastatic deposit, resulting in
overestimation of the size of the metastatic foci. In our
previous study, MR imaging with interstitial injection of
SPIO was evaluated for the detection of metastases in
sentinel nodes, which were localized by CT-LG in 102
patients with breast cancer [13]. The sensitivity, specifi-
city, and accuracy of MR imaging for the diagnosis of
sentinel node metastases were 84%, 91%, and 89%,
respectively. In 40% of patients with micro-metastases,
metastases were not detected, but all patients with macro-
metastases were successfully identified. False negatives
may be due to micro-metastases. Of the 7 false-positive re-
sults, 6 were due to a prominent fatty hilum. False posi-
tives may be due to prominent fatty tissue and insufficient
transition of SPIO to sentinel nodes. Fat-saturated images,
a 3 T MR system and special coil for MR imaging may be
needed to clearly identify small metastatic foci.
However, the clinical implication of micro-metastases
is debatable. De Boer et al. reported that the presence of
both isolated tumor cells and micro-metastases was
associated with reduced disease-free survival among
patients who did not receive systemic adjuvant therapy
[22]. In patients with isolated tumor cells and micro-
metastases who received adjuvant therapy, disease-free
survival was improved. In the systematic review, the pres-
ence of micro-metastases in axillary lymph nodes detected
on single-section examination was associated with poorer
disease-free and overall survival [23], while Hansen et al.
reported that patients with micro-metastases do not have
a worse disease-free or overall survival than sentinel node-
negative patients [24]. Whether intensive identification of
the existence of small disease foci is needed in clinical
practice is an urgent problem.
There were some limitations to our study. There was a
relatively small number of metastatic nodes in our series.
This was due to the selection of patients with T1-2 breast
cancers and clinically negative nodes, who do not have
many metastatic axillary nodes. In addition, it is unclear
whether the 50% cut-off value was appropriate. The 50%
cut-off value was applied according to the diagnostic
guidelines for USPIO-enhanced MR imaging, and for
high-signal intensity in which more than 50% of the node
was observed in sentinel nodes with macro-metastases
[16]. A larger study is needed to find the most appropriate
cut-off value to confirm the results of our study.
Conclusions
High-signal intensity patterns that are uniform or in-
volve more than 50% of the node are features of nodes
with macro-metastases. The area of high-signal intensity
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http://www.biomedcentral.com/1471-2342/13/32correlated with the pathological size of metastases for
nodes with metastases >2 mm in this series.
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